These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11479072)

  • 1. Preventing schizophrenia and Alzheimer disease: comparative ethics.
    Post SG
    Schizophr Res; 2001 Aug; 51(1):103-8. PubMed ID: 11479072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future scenarios for the prevention and delay of Alzheimer disease onset in high-risk groups. An ethical perspective.
    Post SG
    Am J Prev Med; 1999 Feb; 16(2):105-10. PubMed ID: 10343886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethics of early prevention in schizophrenia.
    Rosen A
    Aust N Z J Psychiatry; 2000 Nov; 34 Suppl():S208-12. PubMed ID: 11129311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines for addressing ethical and legal issues in Alzheimer disease research: a position paper. National Institute on Aging.
    High DM; Whitehouse PJ; Post SG; Berg L
    Alzheimer Dis Assoc Disord; 1994; 8 Suppl 4():66-74. PubMed ID: 7695858
    [No Abstract]   [Full Text] [Related]  

  • 5. Ethical issues in early diagnosis and prevention of Alzheimer disease.
    Whitehouse PJ
    Dialogues Clin Neurosci; 2019 Mar; 21(1):101-108. PubMed ID: 31607785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials.
    Kim SY; Karlawish J; Berkman BE
    Neurology; 2015 Apr; 84(14):1488-94. PubMed ID: 25762713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of schizophrenia: future ethics.
    McClelland R
    Ann Ist Super Sanita; 1997; 33(4):505-7. PubMed ID: 9616961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein E genotyping for Alzheimer's disease: ethical concerns and implications for clinical practice.
    Abyad A; al Imad R
    J Med Liban; 1999; 47(5):291-4. PubMed ID: 10887530
    [No Abstract]   [Full Text] [Related]  

  • 9. Preventing severe mental illnesses--new prospects and ethical challenges.
    Schaffner KF; McGorry PD
    Schizophr Res; 2001 Aug; 51(1):3-15. PubMed ID: 11479061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethical concerns in the research and treatment of complex disease.
    Parker LS
    Trends Genet; 1995 Dec; 11(12):520-3. PubMed ID: 8533171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ethics and neuropsychological assessment].
    Thomas-Antérion C; Barbeau E
    Geriatr Psychol Neuropsychiatr Vieil; 2012 Dec; 10(4):445-52. PubMed ID: 23250025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethics of the early intervention in the treatment of schizophrenia.
    Filaković P; Degmecić D; Koić E; Benić D
    Psychiatr Danub; 2007 Sep; 19(3):209-15. PubMed ID: 17914322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between polygenic risk for schizophrenia, neurocognition and social cognition across development.
    Germine L; Robinson EB; Smoller JW; Calkins ME; Moore TM; Hakonarson H; Daly MJ; Lee PH; Holmes AJ; Buckner RL; Gur RC; Gur RE
    Transl Psychiatry; 2016 Oct; 6(10):e924. PubMed ID: 27754483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument.
    Palmer BW; Dunn LB; Appelbaum PS; Mudaliar S; Thal L; Henry R; Golshan S; Jeste DV
    Arch Gen Psychiatry; 2005 Jul; 62(7):726-33. PubMed ID: 15997013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining the competency of Alzheimer patients to consent to treatment and research.
    Marson DC; Schmitt FA; Ingram KK; Harrell LE
    Alzheimer Dis Assoc Disord; 1994; 8 Suppl 4():5-18. PubMed ID: 7695856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discourse ethics: research, dementia, and communication.
    Post SG; Ripich DN; Whitehouse PJ
    Alzheimer Dis Assoc Disord; 1994; 8(Suppl. 4):58-65. PubMed ID: 11657675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychological assessment of attention and its pathology in the Israeli cohort.
    Mirsky AF; Ingraham LJ; Kugelmass S
    Schizophr Bull; 1995; 21(2):193-204. PubMed ID: 7631167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive profiles of healthy siblings of schizophrenia patients: application of the cognitive domains of the MATRICS consensus battery.
    Nam HJ; Kim N; Park T; Oh S; Jeon HO; Yoon SC; Lee YS; Lee WK; Ha K; Kim JH; Hong KS
    World J Biol Psychiatry; 2009; 10(4 Pt 2):452-60. PubMed ID: 18792857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychological change in young people at high risk for schizophrenia: results from the first two neuropsychological assessments of the Edinburgh High Risk Study.
    Cosway R; Byrne M; Clafferty R; Hodges A; Grant E; Abukmeil SS; Lawrie SM; Miller P; Johnstone EC
    Psychol Med; 2000 Sep; 30(5):1111-21. PubMed ID: 12027047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease.
    Peters KR; Lynn Beattie B; Feldman HH; Illes J
    Prog Neurobiol; 2013 Nov; 110():114-23. PubMed ID: 23348495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.